Discussion  by unknown
Appendix B. Within-group analysis
Discussion
Dr Mohan Reddy (Stanford, Calif). I have a couple of ques-
tions for you. First, where did you obtain your samples? Was it
from the umbilical artery or from the venous site? Second, have
you measured umbilical artery blood flows during this study?
There is no significant difference in your placental function pa-
rameters, at least the blood gases.
Dr Carotti. Samples were always obtained from the right
carotid artery, which was cannulated during the instrumentation of
the animal.
We did not measure umbilical artery blood flow, and we are
aware that this point may be a limitation of our study. However, I
think that the main limitation of the study was the long run of CB
without using an oxygenator. In fact, a linear relationship between
CB duration and increase of placental vascular resistance has been
demonstrated and is possibly enhanced by the absence of an
oxygenator, leading to progressive placental dysfunction. Such a
choice could explain why we did not find significant differences of
blood gases between groups. However, although aware of such
limitation, we selected this policy of CB anyway, because of the
known linear relationship existing between bypass duration and
related inflammatory reaction. In fact, the main aim of our study
was to test the effects of steroids and CVVHD on the inflammatory
response to CB.
TABLE B-1. Maternal pretreatment with betamethasone
Test pairs
T0-T60
(P value)
T0-T150
(P value)
pH ns .05
PaCO2 (mm Hg) .05 <.05
HCO3
 (mmol/L) ns .05
O2 Sat (%) .05 .05
HR (beats/min) ns ns
SBP (mm Hg) .05 ns
Glucose (mg/dL) <.05 ns
Lactate (mmol/L) <.05 <.05
ET1 (pg/mL) ns <.05
ET2 (pg/mL) <.05 ns
ET3 (pg/mL) <.05 ns
CRF (pg/mL) ns ns
P value (Wilcoxon signed-rank test): bold font when T0 is less than T60 or
T150, and italic font when T0 is greater than T60 or T150. Sat, Arterial oxygen
saturation; HR, heart rate; SBP, systolic arterial blood pressure; ET, endo-
thelin; T0 , baseline; T60 , end of cardiac bypass; T150 , end of the experiment.
TABLE B-2. Fetal treatment with methylprednisolone
Test pairs
T0-T60
(P value)
T0-T150
(P value)
pH .05 .05
PaCO2 (mm Hg) <.05 <.05
HCO3
 (mmol/L) ns <.05
O2 Sat (%) .05 .05
HR (beats/min) ns ns
SBP (mm Hg) ns ns
Glucose (mg/dL) <.05 ns
Lactate (mmol/L) <.05 <.05
ET1 (pg/mL) ns ns
ET2 (pg/mL) ns ns
ET3 (pg/mL) ns <.05
CRF (pg/mL) ns ns
P value (Wilcoxon signed-rank test): bold font when T0 is less than T60 or
T150, and italic font when T0 is greater than T60 or T150. Sat, Arterial oxygen
saturation; HR, heart rate; SBP, systolic arterial blood pressure; ET, endo-
thelin; T0 , baseline; T60 , end of cardiac bypass; T150 , end of the experiment.
TABLE B-3. Fetal CVVHD
Test pairs
T0-T60
(P value)
T0-T150
(P value)
pH .05 .05
PaCO2 (mm Hg) <.05 <.05
HCO3
 (mmol/L) <.05 ns
O2 Sat (%) .05 .05
HR (beats/min) ns ns
SBP (mm Hg) ns ns
Glucose (mg/dL) <.05 ns
Lactate (mmol/L) ns <.05
ET1 (pg/mL) ns ns
ET2 (pg/mL) ns ns
ET3 (pg/mL) ns ns
CRF (pg/mL) ns ns
P value (Wilcoxon signed-rank test): bold font when T0 is less than T60 or
T150, and italic font when T0 is greater than T60 or T150. Sat, Arterial oxygen
saturation; HR, heart rate; SBP, systolic arterial blood pressure; ET, endo-
thelin; T0 , baseline; T60 , end of cardiac bypass; T150 , end of the experiment.
TABLE B-4. Control animals
Test pairs
T0-T60
(P value)
T0-T150
(P value)
pH .05 .05
PaCO2 (mm Hg) <.05 <.05
HCO3
 (mmol/L) ns ns
O2 Sat (%) .05 .05
HR (beats/min) ns ns
SBP (mm Hg) .05 ns
Glucose (mg/dL) <.05 <.05
Lactate (mmol/L) <.05 <.05
ET1 (pg/mL) ns ns
ET2 (pg/mL) ns ns
ET3 (pg/mL) ns ns
CRF (pg/mL) ns ns
P value (Wilcoxon signed-rank test): bold font when T0 is less than T60 or
T150, and italic font when T0 is greater than T60 or T150. Sat, Arterial oxygen
saturation; HR, heart rate; SBP, systolic arterial blood pressure; ET, endo-
thelin; T0 , baseline; T60 , end of cardiac bypass; T150 , end of the experiment.
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Dr Reddy. The thing that seemed to make most difference was
using an in-line axial flow pump in our experience, rather than any
of the agents. We did not test hemodiafiltration, but that is some-
thing we will probably consider
Dr Carotti. I agree that the choice of the circuit is a main issue.
Actually, we had some problems with the circuit that included an
in-line axial flow pump, mainly during hemodiafiltration, because
in general we could not obtain a blood flow rate higher than 1
L/min at the fastest pump speed, using a 16F venous cannula and
a 3.5-mm arterial cannula. During filter perfusion, the pump ap-
peared to be performing somewhat less well, and this probably
caused some fetoplacental hypoperfusion in some of CVVHD
fetuses. This is probably the main reason why CVVHD fetuses,
which were performing very well during extracorporeal circula-
tion, deteriorated quickly after discontinuation of the procedure.
Dr Renato S. Assad (Sa˜o Paulo, Brazil). Due to the limitations
of the cannula size, if you add a more complex circuit like a
hemofilter in the circuit, I think you are going to need more flow.
And due to the very small size of the patients we are planning to
treat, maybe we should use an endothelium block rather than a
hemofilter as Dr Hanley’s group in San Francisco has shown. They
use an endothelium block with an improvement of placental func-
tion after fetal cardiac bypass. Maybe going for something simple,
rather than adding a more complex circuit, would be better for
future clinical applications. I just would like to make this insight.
Dr Carotti. I agree with you that some pharmacologic agents
can block the activity of the endothelium. However, in our exper-
iment, the endothelium was probably only the last effector of an
inflammatory amplification loop.
In our study we used hemodiafiltration without net ultrafiltra-
tion, a sort of hemodialysis, which per se did not eliminate great
amounts of endothelins. We probably had a greater effect by
removing even small amounts of molecules responsible for the
initiation of an inflammatory amplification loop.
Therefore, we think that CVVHD helped in removing many
more substances than endothelin alone. This is probably why we
did not find the rebound of endothelins in animals treated by
CVVHD, which one could have expected had removal of endo-
thelins been managed by hemodiafiltration only.
CVVHD probably blocked an inflammatory amplification loop.
I do not think that antagonists or endothelin blockers would have
obtained the same effect.
Dr Frank L. Hanley (Stanford, Calif). I want to reemphasize
the concern about your perfusion rates overall. The pHs in all of
your groups drop fairly dramatically no matter what you did. With
the filtration system in the circuit that is pulling off some of your
flows, do you have any idea what your effective fetal placental
perfusion rate was? You may have had hypoperfusion right from
the very beginning here, which brings up another whole set of
factors.
Dr Carotti. This is a good point. During our preliminary
experience with fetal CB, we were impressed by the flow limita-
tions of an in-line axial flow pump (Hemopump) included within
a conventional circuit. For this reason, we conducted an in vitro
study in which we tested the performance of the Hemopump
within the same circuit used for fetal CB at different pump pre-
loads and afterloads. We found that at a preload of 5 mm Hg and
an afterload of 45 mm Hg, which corresponded respectively to the
average mean right atrial and mean systemic blood pressure in our
experiments, the maximal flow rate obtained at the fastest pump
speed was 1 L/min.
After completion of each in vivo experiment, fetal weight was
measured and the estimated blood flow perfusion during bypass
was related to the real weight of each animal. It appeared that we
obtained a blood flow rate of at least 300 mL · kg1 · min1 in all
fetuses but in two of the CVVHD group. In those animals, possibly
because of higher compliance of the system, we had a loss of 20%
to 30% of the maximal flow rate.
So you are right: we got into fetoplacental hypoperfusion
during CVVHD in two animals, and this was due to circuit
limitations.
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